Insider Selling: Atara Biotherapeutics, Inc. (NASDAQ:ATRA) EVP Sells 1,000 Shares of Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) EVP Jill Henrich sold 1,000 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $11.20, for a total value of $11,200.00. Following the sale, the executive vice president now owns 19,378 shares of the company’s stock, valued at $217,033.60. This trade represents a 4.91 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Atara Biotherapeutics Stock Up 0.8 %

ATRA opened at $10.69 on Friday. The business’s fifty day simple moving average is $9.14 and its 200 day simple moving average is $10.11. Atara Biotherapeutics, Inc. has a 52 week low of $6.50 and a 52 week high of $39.50. The firm has a market cap of $61.57 million, a P/E ratio of -0.41 and a beta of 0.50.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.77) by $0.84. The business had revenue of $40.19 million during the quarter, compared to analyst estimates of $23.00 million. During the same period in the previous year, the business posted ($16.50) earnings per share. As a group, equities analysts expect that Atara Biotherapeutics, Inc. will post -12.12 EPS for the current fiscal year.

Hedge Funds Weigh In On Atara Biotherapeutics

Large investors have recently modified their holdings of the company. Redmile Group LLC raised its holdings in shares of Atara Biotherapeutics by 1.7% during the 1st quarter. Redmile Group LLC now owns 9,263,309 shares of the biotechnology company’s stock valued at $6,429,000 after buying an additional 156,863 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in shares of Atara Biotherapeutics by 8,916.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,958,150 shares of the biotechnology company’s stock valued at $3,442,000 after buying an additional 4,903,159 shares during the period. Acadian Asset Management LLC increased its holdings in Atara Biotherapeutics by 49.5% during the 1st quarter. Acadian Asset Management LLC now owns 2,638,687 shares of the biotechnology company’s stock worth $1,830,000 after purchasing an additional 873,133 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in Atara Biotherapeutics by 29.3% during the 1st quarter. BNP Paribas Financial Markets now owns 383,082 shares of the biotechnology company’s stock worth $266,000 after purchasing an additional 86,842 shares during the last quarter. Finally, Vestal Point Capital LP increased its holdings in Atara Biotherapeutics by 11.3% during the 3rd quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock worth $1,014,000 after purchasing an additional 12,677 shares during the last quarter. 70.90% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently commented on ATRA shares. Mizuho upgraded Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and cut their price target for the stock from $25.00 to $18.00 in a research note on Friday, August 16th. Canaccord Genuity Group increased their price objective on Atara Biotherapeutics from $13.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Finally, HC Wainwright reiterated a “neutral” rating on shares of Atara Biotherapeutics in a research report on Wednesday, August 21st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $16.67.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.